Nov 04, 2015

Could Your Blood Type Influence Susceptibility to Alzheimer’s?

A new research study from the University of Sheffield suggests that our blood type may have more of an influence on protecting our brain from disease than previously thought.
A promising development that may have the potential to unveil another piece of the puzzle supporting Alzheimer’s research.

The University of Sheffield journal Brain Research Bulletin, suggests that individuals with ‘Type O’ blood have larger grey matter in the cerebellum. The region of the brain involved with seeing and hearing, memory, emotions, speech and decision making.

Grey matter a major component of the central nervous system, comprising of numerous brain cells including neurons. Often found to be on of the first areas damaged in people with Alzheimer’s disease. People with larger grey matter may have more reserve before negative effects take place. While further research needs to be done, this suggests that our blood type may yet provide some clues to susceptibility.

The aim of the study was to compare the grey matter volumes of 189 cognitively healthy adults. Of the participants, 76 adults had Type O blood, 65 adults had Type A blood while the others had either Type AB or B blood. All participants were scanned using an MRI brain scanning technique to measure the volume of the grey matter. The researchers found that participants with Type O blood had more grey matter in the posterior proportion of the cerebellum. Those with ‘A’, ‘B’ or ‘AB’ blood types had more grey matter volumes in both temporal (responsible for memory and language) and limbic regions (responsible for emotions, memories and arousal) of the brain, including the left hippocampus. With the hippocampus one of the areas of the brain affected by Alzheimer’s disease.

Dr Matteo De Marco, research fellow at the University of Sheffield’s Department of Neuroscience, stated that the findings indicated that individuals with ‘O’ blood type have more protection against particular diseases where the volumetric reduction is seen in temporal regions of the brain, with Alzheimer’s disease being a classic example.

Dr DeMarco was clear to emphasise, however, that the community must not to jump to conclusion and assume that blood type can decrease or increase our risk of dementia. Further, individuals with A, B or AB blood types should not assume that they are at higher risk of dementia or Alzheimer’s until further research is performed. Although still in early stages requiring additional tests and further research. It’s another step forward in the search for a greater understanding for the causes of the disease.

Vicki Tuchtan, Academic Director at Sage Institute of Education

Vicki Tuchtan is the Academic Director at Sage Institute of Education. She oversees learning processes, teaching outcomes, resources and course development. A passionate advocate for bettering standards of Aged Care Training.

Leave a Reply

Your email address will not be published. Required fields are marked *

Advertisement
Advertisement
Advertisement

Should you tell people about a dementia diagnosis?

Sharing the news of a dementia diagnosis might seem daunting. It can be hard to know how to broach such significant news, and you might be concerned about how people will react. While there are good reasons to let people know that you, or someone in your care, has been diagnosed with the condition, the... Read More

In A World Of Chaos, This Story Of Love And Dementia Will Squeeze Your Heart

By Amy Henderson – HelloCare Journalist This world we live in is a bit bonkers. It’s no wonder than as a society we seem to crave love stories, the bigger and more epic the better. We’re inundated with movies that in one way or another explore what it is to love and be loved. We’re... Read More

Why a Drug Treatment for Dementia has Eluded us

Finding a cure for neurodegenerative diseases such as Alzheimer’s is challenging. They’re difficult to diagnose, and drugs struggle to get into the brain as the brain’s blood supply is largely separate to the rest of the body. Not surprisingly, several companies have left this territory in recent years. Last week, pharmaceutical giant Pfizer announced it will stop... Read More
Advertisement
Exit mobile version